

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

REGISTERED OFFICE: 11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON WEST, MUMBAI 400 104

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com

28th September, 2021

To,
The Manager,
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001, India.
Email: corp.relations@bseindia.com

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

In terms of disclosure under Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, Pharmaceutical Business Group (India) Limited Promoter, of Gujarat Themis Biosyn Limited (the Company) hereby submit the disclosure with regard to acquisition of Equity shares of the Company, as per mutual understanding and agreement with Yuhan Corporation, through an off market transaction, , for your information and record.

Thanking you,

Yours faithfully,
For Pharmaceutical Business Group (India) Limited



Kersasp Kalianwala
Director



CC to;
Company: secretary@gtbl.in.net

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

REGISTERED OFFICE: 11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON WEST, MUMBAI 400 104

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com

28th September, 2021

To,
Securities and Exchange Board of India
Plot no.C 4-A, G-Block,
Bandra Kurla Complex,
Bandra East,Mumbai – 400 051.

Dear Sir/ Madam,

Sub: Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1) (a) (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Target Company: Gujarat Themis Biosyn Limited [BSE: 506879]

With reference to the above cited subject, we hereby submit report and demand draft of Rs. 1,50,000/- (Rupees One Lakh and Fifty Thousand only) dated September 24, 2021 in favor of "Securities and Exchange Board of India" payable at Mumbai, as required under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for acquisition of 38,50,000 (Thirty Eight Lakh and Fifty Thousand) equity shares of Yuhan Corporation, by way of inter-se transfer on 17th September 2021, in terms of Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly take the same on record and suitably disseminate to all concerned.

Thanking you,

Yours faithfully,

For Pharmaceutical Business Group (India) Limited

Kersasp Kalianwala
Director



ENCLOSED:

1. Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1) (a) (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2. Demand draft of Rs. 1,50,000/- (Rupees One Lakh and Fifty Thousand only) dated September 24, 2021 In favor of "Securities and Exchange Board of India" payable at Mumbai.

कृपया ध्यान दें
Payee Only



Union Bank

कृपया
Sr. No

41894642

41894642

GOREGAON WEST MUMBAI

24-09-2021

प्राप्त पर अदा करें
ON DEMAND PAY

***** Not Over INR. 1,50,000.00 *****

एन डी एन डी
OR ORDER

SECURITIES AND EXCHANGE BOARD OF INDIA

एन रुपेस

One Lakh Fifty Thousand only

एन रुपेस के लिए

FOR VALUE RECEIVED

₹

*****1,50,000.00

BC. No

41894642

एन यूनियन बैंक
To Union Bank

कृपया यूनियन बैंक ऑफ इंडिया For Union Bank of India

Purchaser: PHARMACEUTICAL BUSINESS GROUP INDIA LTD
MUMBAI - SERVICE BRANCH

PAYABLE AT THE ORDER OF THE ISSUING BANK FOR THREE months only from the date of issue

EM/PD/AE

Key:JYG436605

894642 0000260000 000041 16

Format under Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	General Details	
	a. Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any one acquirer (the correspondent acquirer) with whom SEBI shall correspond.}	PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED. 11/12 Udyog Nagar S.V. Road, Goregaon (West) Mumbai City MAHARASHTRA 400104 INDIA. pbgil.250191@gmail.com. Mobile -9320009789
	b. Whether sender is the acquirer (Y/N)	Yes
	c. If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization)	Not Applicable
	d. Name, address, Tel no. and e-mail of sender, if sender is not the acquirer	Not Applicable
2	Compliance of Regulation 10(7)	
	a. Date of report	28 th September, 2021
	b. Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes; the report is being submitted to SEBI within 21 working days from the date of the acquisition.
	c. Whether the report is accompanied with fees as required under Regulation 10(7)	Yes; INR 1,50,000 (one lakh fifty only) by demand draft No. 894642 issued by 24-09-2021 Union Bank of India in Favor of Securities and Exchange Board of India.
3	Compliance of Regulation 10(5)	
	a. Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed atleast 4 working days before the date of the proposed acquisition.	YES. Copy of the same is attached as Annexure I
	b. Date of Report	24 th July, 2021
4	Compliance of Regulation 10(6)	
	a. Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days of the acquisition.	Yes Copy of the same is attached as Annexure II

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI(Substantial Acquisition of Shares and Takeover Regulations, 2011)



	b.	Date of Report	18 th September, 2021			
5	Details of the Target Company					
	a.	Name & address of TC	GUJARAT THEMIS BIOSYN LTD 69/C, GIDC INDUSTRIAL ESTATE, VAPI VALSAD GUJARAT 396195 INDIA			
	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited- 506879			
6	Details of the acquisition					
	a.	Date of acquisition	17 th September, 2021.			
	b.	Acquisition price per share (in Rs.)	Rs.150 per share.			
	c.	Regulation which would have been triggered off, had the report not been filed under Regulation 10(7). (whether Regulation 3(1), 3(2), 4 or 5)	Regulation 3(1)[Read with 3(3)] and 3(2) of SEBI SAST Regulations, 2011.			
	d.	Shareholding of acquirer(s) and PAC individually in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC (*)	No. of Shares	% w.r.t total share capital of TC
		Name(s) of the acquirer(s) (**) PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED.	3582000	24.65%	7432000	51.15%
		Names of PAC:				
		Themis Medicare Limited	33,69,605	23.19%	33,69,605	23.19%
		Mrs. Jayshree D Patel	70,645	0.49%	70,645	0.49%
		Dr. Sachin Dinesh Patel	7,100	0.05%	7,100	0.05%
		Mrs. Reena S Patel	5,600	0.04%	5,600	0.04%
		Dr. Dinesh Shantilal Patel	4,701	0.03%	4,701	0.03%
		Ms. Anay Rupen Choksi	3,047	0.02%	3,047	0.02%
		Ms. Nysha Rupen Choksi	3,047	0.02%	3,047	0.02%
		Total	70,45,745	48.49%	1,08,95,745	74.99%
	e.	Shareholding of seller/s in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
		Name(s) of the seller(s) (**)				

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI(Substantial Acquisition of Shares and Takeover Regulations, 2011)



		YUHAN CORPORATION.	3850000	26.50%	0	0
7	Information specific to the exemption category to which the instant acquisition belongs - Regulation 10(1)(a)(ii)					
	a.	Provide the names of the seller(s)	YUHAN CORPORATION.			
	b.	Specify the relationship between the acquirer(s) and the seller(s).	The Acquirer(s) and Seller(s) are the promoters of GTBL, since last 03 years.			
	c.	Shareholding of the acquirer and the seller/s in the TC during the three years prior to the proposed acquisition	Year – 1 (FY 2021)	Year -2 (FY 2020)	Year-3 (FY 2019)	
		Acquirer(s) (*) PHARMACEUTICAL BUSINESS GROUP(INDIA) LIMITED	3582000	3582000	3582000	
		Sellers(s)(*) YUHAN CORPORATION.	3850000	3850000	3850000	
	d.	Confirm that the acquirer(s) and the seller/s have been named promoters in the shareholding pattern filed by the target company in terms of the listing agreement or the Takeover Regulations. Provide copies of such filings under the listing agreement or the Takeover Regulations.	Yes, we confirm that Acquirer(s) and Seller(s) have been named as Promoter/ Promoter Groups in the shareholding pattern filed by Gujarat Themis Biosyn Limited in terms of SEBI Takeover Regulations. Copies of Stock Exchange filings for (i) Quarters ending March 31' 2021, (ii) Quarters ending March 31' 2020 (iii) Quarters ending March 31' 2019 are attached as Annexure III			
	e.	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	INR.310.64 per share			
	f.	If shares of the TC are infrequently traded, the price of such shares as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable.			
	g.	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (e) or (f) above as applicable	Yes; we confirm that the acquisition price per share is not higher by more than 25% of the price as calculated in (e) as mentioned above.			
	h.	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed	24 th July, 2021.			

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI(Substantial Acquisition of Shares and Takeover Regulations, 2011)



i.	Whether the acquirers as well as sellers have complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed Takeover Regulations 1997) (Y/N). If yes, specify applicable regulation/s as well as date on which the requisite disclosures were made along with the copies of the same.	Yes; the Acquirer(s) hereby declare that both Acquirer(s) and Seller(s) have complied with the provisions of Chapter V of SEBI Takeover Regulations. The aforesaid disclosure filed by acquirer and seller under Chapter V of SEBI SAST regulations are attached as Annexure IV. Disclosure under Reg. 29(2) <table><tr><td>Name of Acquirer(s)</td><td>Date</td></tr><tr><td>PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED</td><td>18th September, 2021</td></tr></table> <table><tr><td>Name of Seller(s)</td><td>Date</td></tr><tr><td>YUHAN CORPORATION</td><td>17th September, 2021</td></tr></table> Copy of the Disclosure under Re. 30 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is attached as Annexure V.	Name of Acquirer(s)	Date	PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED	18 th September, 2021	Name of Seller(s)	Date	YUHAN CORPORATION	17 th September, 2021
Name of Acquirer(s)	Date									
PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED	18 th September, 2021									
Name of Seller(s)	Date									
YUHAN CORPORATION	17 th September, 2021									
j.	Declaration by the acquirer that all the conditions specified under regulation 10(1) (a) (ii) with respect to exemptions has been duly complied with.	We hereby confirm that all the conditions specified under Regulation 10(1)(a)(ii) with respect to exemptions has been duly complied with.								

I/We hereby declare that the information provided in the instant report is true and nothing has been concealed there from.

Pharmaceutical Business Group (India) Limited

Sign:

Kersasp Kalianwala
Director



Date: 28th September, 2021

Place: Mumbai

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI(Substantial Acquisition of Shares and Takeover Regulations, 2011)

NOTE:

- (*) In case, percentage of shareholding to the total capital is different from percentage of voting rights, indicate percentage of shareholding and voting rights separately.
- (**) Shareholding of each entity shall be shown separately as well as collectively.



The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI(Substantial Acquisition of Shares and Takeover Regulations, 2011)



Annexure I

GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
TEL : 0260-2430027
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

Date: 24th July, 2021

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Email: corp.relations@bseindia.com

Dear Sirs,

Sub: Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.

We write this in continuation to our letter dated 24th July 2021, enclosing herewith intimation under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

In this connection, we have received letter from Pharmaceutical Business Group (India) Limited (Acquirer) stating that there is a correction in point no. 11 of the intimation.

The same is attached below for your record.

Thanking you,

Yours faithfully,
For Gujarat Themis Biosyn Limited

Rahul Soni
Company Secretary





GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA
TEL : 0260-2430027
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

Date: 24th July, 2021

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Email: corp.relations@bseindia.com

Dear Sirs,

Sub: Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.

We write this in continuation to our letter dated 24th July 2021, enclosing herewith intimation under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

In this connection, we have received letter from Pharmaceutical Business Group (India) Limited (Acquirer) stating that there is a correction in point no. 11 of the intimation.

The same is attached below for your record.

Thanking you,

Yours faithfully,
For Gujarat Themis Biosyn Limited

Rahul Soni
Company Secretary



REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

Date: 24th July, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001
Email: corp.relations@bseindia.com

Dear Sirs

CORRIGENDUM

Sub: Prior Intimation under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011 for proposed acquisition of shares.

We write this in continuation to our letter dated 24th July 2021, enclosing therewith intimation/disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011.

In this connection, we have to state that, there was an inadvertent error in point no. 11 of the intimation/disclosure under Regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011.

Point no. 11 should be read as mentioned below:

11	Shareholding Details	Before the proposed Transaction		After the proposed transaction	
	a. Acquirer(s) Pharmaceutical Business Group(India) Limited and PACs (other than sellers) -	No of Shares/voting rights	% w.r.t total share capital of TC	No of Shares/voting rights	% w.r.t total share capital of TC
1.	Pharmaceutical Business Group [India] Ltd	35,82,000	24.65	74,32,000	51.15
2.	Themis Medicare Limited	33,69,605	23.19	33,69,605	23.19
3.	Jayshree D Patel	70,645	0.49	70,645	0.49
4.	Sachin Dinesh Patel	7,100	0.05	7,100	0.05
5.	Reena S Patel	5,600	0.04	5,600	0.04
6.	Dinesh Shantilal Patel	4,701	0.03	4,701	0.03
7.	Anay Rupen Choksi	3,047	0.02	3,047	0.02
8.	Nysha Rupen Choksi	3,047	0.02	3,047	0.02
	Total	70,45,745	48.49%	1,08,95,745	74.99%
	b. Seller (s) Yuhan Corporation	38,50,000	26.50%	NIL	NIL

Pharmaceutical
Business Group
(India) Limited

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

Please take the same on your record.

Thanking you,

Yours faithfully,

For Pharmaceutical Business Group (India) Limited

JAYSHREE

DINESH

PATEL

Jayshree D. Patel

Director

Digitally signed by Jayshree D. Patel
DN: cn=Jayshree D. Patel, o=Pharmaceutical Business Group (India) Limited, email=jayshree.d.patel@themismedicare.com, c=IN
Date: 2023.07.26 15:25:25 +05'30'



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195, DIST. VALSAD, GUJARAT, INDIA.
TEL : 0260-2430027
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

Date: 26th July, 2021

To,
Rakesh Parekh
Special Assistant
Listing Compliance
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Email: corp.relations@bseindia.com

Dear Sirs,

Sub: Revised Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.

We refer to your email dated 26th July, 2021 asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011.

In this connection, we have received revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011 from Pharmaceutical Business Group (India) Limited (Acquirer).

We are forwarding herewith the same.

Please take the same on record.

Thanking you,

Yours faithfully,
For Gujarat Themis Biosyn Limited

Rahul Soni
Company Secretary



REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

To,
Rakesh Parekh
Special Assistant
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001, India.
Email: corp.relations@bseindia.com

Dear Sirs,

Sub: Revised Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.

With reference to your email dated 26th July, 2021 asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Please take the same on record the revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

CC to;
Company: secretary@gtbl.in.net

Thanking you,

Yours faithfully,
For Pharmaceutical Business Group (India) Limited



Kersasp Kalianwala
Director



Revised Disclosure under regulation 10 (5)

1	Name of the Target Company	Gujarat Themis Biosyn Limited
2	Name of the Acquirer	Pharmaceutical Business Group (India) Limited
3	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	Yes. Pharmaceutical Business Group (India) Limited is one of the promoters of the Target Company. Not applicable
4	Details of the proposed acquisition a. Name of the person(s) from whom shares are acquired b. Proposed date of Acquisition c. Number of shares to be acquired from each person mentioned in 4 (a) above d. Total shares to be acquired as % of share capital of TC . e. Price at which shares are proposed to be acquired f. Rationale, if any, for the proposed transfer	Yuhan Corporation On or after July 30, 2021 38,50,000 (26.50 %) Rs. 150/- per share Inter-se transfer of shares amongst promoters of the Company, as per the mutual agreement between the promoters.



Revised Disclosure under regulation 10 (5)

5	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Regulation 10(1)(a)(ii) of SEBI (SAST) Regulation, 2011
6	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on BSE Ltd, the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	Rs. 310.64 Per share
7	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not applicable
8	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above. -
9	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Yes, the Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulation, 2011
10	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with	The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.



Revised Disclosure under regulation 10 (5)

11	Shareholding Details	Before the proposed Transaction		After the proposed transaction	
	a. Acquirer(s) and PACs (other than sellers) - Pharmaceutical Business Group(India) Limited	No of Shares/voting rights	% w.r.t total share capital of TC	No of Shares/voting rights	% w.r.t total share capital of TC
1.	Pharmaceutical Business Group [India] Ltd	35,82,000	24.65	74,32,000	51.15
2.	Themis Medicare Limited	33,69,605	23.19	33,69,605	23.19
3.	Jayshree D Patel	70,645	0.49	70,645	0.49
4.	Sachin Dinesh Patel	7,100	0.05	7,100	0.05
5.	Reena S Patel	5,600	0.04	5,600	0.04
6.	Dinesh Shantilal Patel	4,701	0.03	4,701	0.03
7.	Anay Rupen Choksi	3,047	0.02	3,047	0.02
8.	Nysha Rupen Choksi	3,047	0.02	3,047	0.02
	Total	70,45,745	48.49%	1,08,95,745	74.99%
	b. Seller (s) Yuhan Corporation	38,50,000	26.50%	NIL	NIL

For Pharmaceutical Business Group (India) Limited

Kersasp Kalianwala

Kersasp Kalianwala

Director

Place: Mumbai

Date: July 26, 2021



REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

DECLARATION BY PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED (THE ACQUIRER) Regulation
10(5)

The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above.

The Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulations, 2011.

The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.

For PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED



Kersasp Kalianwala
Director



PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

REGISTERED OFFICE: 11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON WEST, MUMBAI 400 104

To,
The Manager,
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001, India.
Email: corp.relations@bseindia.com

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

In terms of disclosure under Regulation 10 (6) SEBI (Substantial Acquisition of Share and Takeover) Regulations, 2011, we, Pharmaceutical Business Group(India) Limited Promoter, of Gujarat Themis Biosyn Limited (the Company) hereby submit the disclosure with regard to acquisition of Equity shares of the Company, as per mutual understanding and agreement with Yuhan Corporation , through an off market transaction, , for your information and record.

Thanking you,

Yours faithfully,
For Pharmaceutical Business Group (India) Limited


Kersasp Kalianwala
Director



CC to;
Company: secretary@gtbl.in.net

Format for Disclosures under Regulation 10(6) -Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

1	Name of target Company (TC)	Gujarat Themis Biosyn Limited	
2	Name of the acquirer(s)	Acquirer Pharmaceutical Business Group (India) Limited	
3	Name of the Stock Exchange where shares of the TC are listed	BSE Limited	
4	Details of the transaction including rationale, if any, for the transfer/acquisition of shares.	Inter-se transfer of 38, 50,000 Equity Shares	
5	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10 (1)(a)(i) and 10(1)(a)(ii) of SEBI (SAST) the acquirer is exempted from Regulation, 2011.	
6	Whether disclosure of proposed acquisition was required to acquisition was required to be made under regulation 10(5).;and if so	Yes	
	Whether disclosure made and whether it was made within the time line specified under the regulations.	Yes, declaration under Regulation 10 (5) was made within the timeline specified under the regulations.	
	Date of filing with the Stock exchange	July 24, 2021	
7	Details of acquisition	Disclosures required to be made under Regulation 10(5)	Whether the disclosures under regulation 10 (5) are Actually made
		Yes	Yes
	a Name of the Transferor	Yuhan Corporation	
	b Date of acquisition	17 th September, 2021	
	c Number of Equity Shares shares/voting rights in respect of the acquisitions from each person mentioned in 7(a) above	38,50,000 Equity Shares being the entire shareholding held by the Yuhan Corporation. which is 26.50% voting rights	
	d Total shares proposed to be acquired/ actually acquired % of diluted Share Capital	38,50,000 shares actually acquired being 26.50% of share capital	
	e Price at which shares are proposed to be acquired / actually acquired	Rs. 150 per share	
8	Shareholding details	Pre transaction	Post transaction

Amrutha



			No. of shares held	w.r.t to % of the total capital of the TC	No. of shares held	w.r.t to % of the total capital of the TC
	a	Acquirer/Transferee				
		Pharmaceutical Business group (India) Limited	35,82,000	24.65%	74,32,000	51.15%
	b	Seller/Transferor				
		Yuhan Corporation	38,50,000	26.50%	NIL	NIL

For PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

Kersasp Kalianwala
Kersasp Kalianwala
Director



Place: Mumbai

Date: 18th September, 2021



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter Ending : March 2021

Statement showing shareholding pattern of the Promoter and Promoter Group

Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	Total nos. shares held	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) As a % of (A1+B1+C2)	Number of equity shares held in dematerialized form
A1) Indian				0.00	
Individuals/Hindu undivided Family	6	94,140	94,140	0.65	94,139
Jayshree D Patel	1	70,645	70,645	0.49	70,645
Sachin Dinesh Patel	1	7,100	7,100	0.05	7,100
Reena S Patel	1	5,600	5,600	0.04	5,600
Dinesh Shantilal Patel	1	4,701	4,701	0.03	4,700
Anay Rupen Choksi	1	3,047	3,047	0.02	3,047
Nysha Rupen Choksi	1	3,047	3,047	0.02	3,047
Any Other (specify)	2	69,51,605	69,51,605	47.85	69,51,605
Pharmaceutical Business Group [India] Ltd	1	35,82,000	35,82,000	24.65	35,82,000
Themis Medicare Limited	1	33,69,605	33,69,605	23.19	33,69,605
Sub Total A1	8	70,45,745	70,45,745	48.50	70,45,744
A2) Foreign				0.00	
Any Other (specify)	1	38,50,000	38,50,000	26.50	38,50,000
Yuhan Corporation	1	38,50,000	38,50,000	26.50	38,50,000
Sub Total A2	1	38,50,000	38,50,000	26.50	38,50,000
A=A1+A2	9	1,08,95,745	1,08,95,745	74.99	1,08,95,744



Shareholding Pattern Public Shareholder

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2021

Statement showing shareholding pattern of the Public shareholder

Category & Name of the Shareholders	No. of shareholder	No. of fully paid up equity shares held	Total no shares held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	No. of Voting Rights	Total as a % of Total Voting right	No. of equity shares held in dematerialized form (Not Applicable)
B1) Institutions	0	0		0.00		0.00	
Mutual Funds/	2	2800	2,800	0.02	2,800	0.02	
Financial Institutions/ Banks	2	2100	2,100	0.01	2,100	0.01	
Sub Total B1	4	4900	4,900	0.03	4,900	0.03	
B2) Central Government/ State Government(s)/ President of India	0	0		0.00		0.00	
B3) Non-Institutions	0	0		0.00		0.00	
Individual share capital upto Rs. 2 Lacs	9538	2886847	28,86,847	19.87	28,86,847	19.87	26,22,215
Individual share capital in excess of Rs. 2 Lacs	5	320172	3,20,172	2.20	3,20,172	2.20	3,20,172
Any Other (specify)	619	421038	4,21,038	2.90	4,21,038	2.90	3,80,038
Trusts	3	1650	1,650	0.01	1,650	0.01	1,600
HUF	170	186905	1,86,905	1.29	1,86,905	1.29	1,86,405
Non-Resident Indian (NRI)	344	133734	1,33,734	0.92	1,33,734	0.92	1,02,284
Clearing Members	32	12368	12,368	0.09	12,368	0.09	12,368
Bodies Corporate	70	86381	86,381	0.59	86,381	0.59	77,381
Sub Total B3	10162	3628057	36,28,057	24.97	36,28,057	24.97	33,22,425
B=B1+B2+B3	10166	3632957	36,32,957	25.01	36,32,957	25.01	33,22,425

Details of the shareholders acting as persons in Concert including their Shareholding (No. and %):

Details of Shares which remain unclaimed may be given here along with details such as number of shareholders, outstanding shares held in demat/unclaimed suspense account, voting rights which are frozen etc.

Note

- (1) PAN would not be displayed on website of Stock Exchange(s).
- (2) The above format needs to disclose name of all holders holding more than 1% of total number of shares
- (3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern Non Promoter-Non Public

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2021

Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the Shareholders(I)	No. of shareholder(III)	No. of fully paid up equity shares held(IV)	Total no. shares held(VII = IV+V+VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)/(VIII)	Number of equity shares held in dematerialized form(XIV)(Not Applicable)
C1)					
Custodian/DR Holder	0	0		0.00	
C2) Employee Benefit Trust	0	0		0.00	

Note

(1) PAN would not be displayed on website of Stock Exchange(s).

(2) The above format needs to disclose name of all holders holding more than 1% of total number of shares

(3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2021

Details of disclosure made by the Trading Members holding 1% or more of the Total No. of shares of the company.

Sl No.	Name of the Trading Member	Name of the Beneficial Owner	No. of shares held	% of total no. of shares	Date of reporting by the Trading Member
-	NIL	NIL	NIL	NIL	NIL



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter Ending : March 2020

Statement showing shareholding pattern of the Promoter and Promoter Group

Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	Total nos. shares held	Shareholding as a % of total no. of shares (as noted in para SCRR, 1957) As a % of (A+B+L2)	Number of equity shares held in dematerialized form
A1) Indian				0.00	
Individuals/Hindu undivided Family	6	94,140	94,140	0.65	94,139
Jayshree D Patel	1	70,645	70,645	0.49	70,645
Sachin Dinesh Patel	1	7,100	7,100	0.05	7,100
Reena S Patel	1	5,600	5,600	0.04	5,600
Dinesh Shantilal Patel	1	4,701	4,701	0.03	4,700
Anay Rupen Choksi	1	3,047	3,047	0.02	3,047
Nysha Rupen Choksi	1	3,047	3,047	0.02	3,047
Any Other (specify)	2	69,51,605	69,51,605	47.85	69,51,605
Pharmaceutical Business Group [India] Ltd	1	35,82,000	35,82,000	24.65	35,82,000
Themis Medicare Limited	1	33,69,605	33,69,605	23.19	33,69,605
Sub Total A1	8	70,45,745	70,45,745	48.50	70,45,744
A2) Foreign				0.00	
Any Other (specify)	1	38,50,000	38,50,000	26.50	38,50,000
Yuhan Corporation	1	38,50,000	38,50,000	26.50	38,50,000
Sub Total A2	1	38,50,000	38,50,000	26.50	38,50,000
A=A1+A2	9	1,08,95,745	1,08,95,745	74.99	1,08,95,744



Shareholding Pattern Public Shareholder

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2020

Statement showing shareholding pattern of the Public shareholder

Category & Name of the Shareholders	No. of shareholder	No. of fully paid up equity shares held	Total no. shares held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	No. of Voting Rights	Total % of Total Voting right	No. of equity shares held in dematerialized form (if Applicable)
B1) Institutions	0	0		0.00		0.00	
Mutual Funds/	2	2800	2,800	0.02	2,800	0.02	
Financial Institutions/ Banks	2	2100	2,100	0.01	2,100	0.01	
Sub Total B1	4	4900	4,900	0.03	4,900	0.03	
B2) Central Government/ State Government(s)/ President of India	0	0		0.00		0.00	
B3) Non-Institutions	0	0		0.00		0.00	
Individual share capital upto Rs. 2 Lacs	6942	2780912	27,80,912	19.14	27,80,912	19.14	25,12,980
Individual share capital in excess of Rs. 2 Lacs	5	351889	3,51,889	2.42	3,51,889	2.42	3,51,889
Any Other (specify)	486	495256	4,95,256	3.41	4,95,256	3.41	4,54,556
Trusts	3	20150	20,150	0.14	20,150	0.14	20,100
HUF	135	149304	1,49,304	1.03	1,49,304	1.03	1,49,304
Non-Resident Indian (NRI)	251	116477	1,16,477	0.80	1,16,477	0.80	84,827
Clearing Members	30	22201	22,201	0.15	22,201	0.15	22,201
Bodies Corporate	67	187124	1,87,124	1.29	1,87,124	1.29	1,78,124
Sub Total B3	7433	3628057	36,28,057	24.97	36,28,057	24.97	33,19,425
B=B1+B2+B3	7437	3632957	36,32,957	25.01	36,32,957	25.01	33,19,425

Details of the shareholders acting as persons in Concert including their Shareholding (No. and %):

Details of Shares which remain unclaimed may be given here along with details such as number of shareholders, outstanding shares held in demat/unclaimed suspense account, voting rights which are frozen etc.

Note

(1) PAN would not be displayed on website of Stock Exchange(s).

(2) The above format needs to disclose name of all holders holding more than 1% of total number of shares

(3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern Non Promoter-Non Public

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2020

Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the Shareholders(I)	No. of shareholder(III)	No. of fully paid up equity shares held(IV)	Total no. shares held(VII = IV+V+VI)	Shareholding % calculated as per SCRR 1957 As a % of (A+B+C2)(VIII)	% number of equity shares held in dematerialized form(XIV)(Not Applicable)
C1)					
Custodian/DR Holder	0	0		0.00	
C2) Employee Benefit Trust	0	0		0.00	

Note

(1) PAN would not be displayed on website of Stock Exchange(s).

(2) The above format needs to disclose name of all holders holding more than 1% of total number of shares

(3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2020

Details of disclosure made by the Trading Members holding 1% or more of the Total No. of shares of the company.

Sl No	Name of the Trading Member	Name of the Beneficial Owner	No. of shares held	% of total no. of shares	Date of reporting by the Trading Member
-	NIL	NIL	NIL	NIL	NIL



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter Ending : March 2019

Statement showing shareholding pattern of the Promoter and Promoter Group

Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	Total nos. shares held	Shareholding as a % of total no. of shares calculated as per SCRR, 1957/As a % of (A+B+C)	Number of equity shares held in dematerialized form
A1) Indian				0.00	
Individuals/Hindu undivided Family	6	94,140	94,140	0.65	94,139
Jayshree D Patel	1	70,645	70,645	0.49	70,645
Sachin Dinesh Patel	1	7,100	7,100	0.05	7,100
Reena S Patel	1	5,600	5,600	0.04	5,600
Dinesh Shantilal Patel	1	4,701	4,701	0.03	4,700
Anay Rupen Choksi	1	3,047	3,047	0.02	3,047
Nysha Rupen Choksi	1	3,047	3,047	0.02	3,047
Any Other (specify)	2	69,51,605	69,51,605	47.85	69,51,605
Pharmaceutical Business Group [India] Ltd	1	35,82,000	35,82,000	24.65	35,82,000
Themis Medicare Limited	1	33,69,605	33,69,605	23.19	33,69,605
Sub Total A1	8	70,45,745	70,45,745	48.50	70,45,744
A2) Foreign				0.00	
Any Other (specify)	1	38,50,000	38,50,000	26.50	38,50,000
Yuhan Corporation	1	38,50,000	38,50,000	26.50	38,50,000
Sub Total A2	1	38,50,000	38,50,000	26.50	38,50,000
A=A1+A2	9	1,08,95,745	1,08,95,745	74.99	1,08,95,744



Shareholding Pattern Public Shareholder

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2019

Statement showing shareholding pattern of the Public shareholder

Category & Name of the Shareholders	No. of shareholder	No. of fully paid up equity shares held	Total no. shares held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	No. of Voting Rights	Total no. % of total Voting right	No. of equity shares held in dematerialized form (Not Applicable)
B1) Institutions	0	0		0.00		0.00	
Mutual Funds/	2	2800	2,800	0.02	2,800	0.02	
Financial Institutions/ Banks	2	2100	2,100	0.01	2,100	0.01	
Sub Total B1	4	4900	4,900	0.03	4,900	0.03	
B2) Central Government/ State Government(s)/ President of India	0	0		0.00		0.00	
B3) Non-Institutions	0	0		0.00		0.00	
Individual share capital upto Rs. 2 Lacs	6940	2824678	28,24,678	19.44	28,24,678	19.44	25,47,846
Individual share capital in excess of Rs. 2 Lacs	4	329500	3,29,500	2.27	3,29,500	2.27	3,29,500
Dipak Kanayalal Shah	1	150000	1,50,000	1.03	1,50,000	1.03	1,50,000
Any Other (specify)	509	473879	4,73,879	3.26	4,73,879	3.26	4,29,779
Trusts	4	20200	20,200	0.14	20,200	0.14	20,150
HUF	154	155752	1,55,752	1.07	1,55,752	1.07	1,55,752
Non-Resident Indian (NRI)	249	119019	1,19,019	0.82	1,19,019	0.82	85,569
Clearing Members	26	25549	25,549	0.18	25,549	0.18	25,549
Bodies Corporate	76	153359	1,53,359	1.06	1,53,359	1.06	1,42,759
Sub Total B3	7453	3628057	36,28,057	24.97	36,28,057	24.97	33,07,125
B=B1+B2+B3	7457	3632957	36,32,957	25.01	36,32,957	25.01	33,07,125

Details of the shareholders acting as persons in Concert including their Shareholding (No. and %):

Details of Shares which remain unclaimed may be given here along with details such as number of shareholders, outstanding shares held in demat/unclaimed suspense account, voting rights which are frozen etc.

Note

(1) PAN would not be displayed on website of Stock Exchange(s).

(2) The above format needs to disclose name of all holders holding more than 1% of total number of shares

(3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern Non Promoter-Non Public

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2019

Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the Shareholders(I)	No. of shareholder(III)	No. of fully paid up equity shares held(IV)	Total no. shares held(VII = IV+V+VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)(VIII)	Number of equity shares held in dematerialized form(XIV)(Not Applicable)
C1)					
Custodian/DR Holder	0	0		0.00	
C2) Employee Benefit Trust	0	0		0.00	

Note

(1) PAN would not be displayed on website of Stock Exchange(s).

(2) The above format needs to disclose name of all holders holding more than 1% of total number of shares

(3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available,.



Shareholding Pattern

GUJARAT THEMIS BIOSYN LTD.

Scrip Code : 506879

Quarter ending : March 2019

Details of disclosure made by the Trading Members holding 1% or more of the Total No. of shares of the company.

Sl. No.	Name of the Trading Member	Name of the Beneficial Owner	No. of shares held	% of total no. of shares	Date of reporting by the Trading Member
-	NIL	NIL	NIL	NIL	NIL

Annexure IV

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

REGISTERED OFFICE: 11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON WEST, MUMBAI 400 104

To,
The Manager,
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001, India.
Email: corp.relations@bseindia.com

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

In terms of disclosure under Regulation 29 (2) SEBI (Substantial Acquisition of Share and Takeover) Regulations, 2011, we, Pharmaceutical Business Group(India) Limited Promoter, of Gujarat Themis Biosyn Limited (the Company) hereby submit the disclosure with regard to acquisition of Equity shares of the Company, as per mutual understanding and agreement with Yuhan Corporation , through an off market transaction, for your information and record.

Thanking you,

Yours faithfully,
For Pharmaceutical Business Group (India) Limited


Kersasp Kalianwala
Director



CC to;
Company: secretary@gtbl.in.net

ANNEXURE-2

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company(TC)	Gujarat Themis Biosyn Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC)with the acquirer	Acquirer: Pharmaceutical Business Group (India) Limited PAC: Themis Medicare Limited Jayshree D Patel Sachin Dinesh Patel Reena S Patel Dinesh Shantilal Patel Anay Rupen Choksi Nysha Rupen Choksi		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE		
Details of the acquisition/disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC(**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	35,82,000	24.65%	24.65%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking /others)	N.A.	N.A.	N.A.
c) Voting rights(VR) otherwise than by shares	N.A.	N.A.	N.A.
d) Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	N.A.	N.A.	N.A.
e) Total(a+b+c+d)	35,82,000	24.65%	24.65%

Amey Chavhan




Details of acquisition/sale				
a)	Shares carrying voting rights acquired/sold	38,50,000	26.50%	26.50%
b)	VRs acquired/sold otherwise than by shares	N.A.	N.A.	N.A.
c)	Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC(specify holding in each category) acquired/sold	N.A.	N.A.	N.A.
d)	Shares encumbered/invoked/released by the acquirer	N.A.	N.A.	N.A.
e)	Total(a+b+c+/-d)	38,50,000	26.50%	26.50%

After the acquisition/sale, holding of:				
a)	Shares carrying voting rights	74,32,000	51.15%	
b)	Shares encumbered with the acquirer	N.A.	N.A.	
c)	VRs otherwise than by shares	N.A.	N.A.	
d)	Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC(specify holding in each category) after acquisition	N.A.	N.A.	
e)	Total(a+b+c+d)	74,32,000	51.15%	51.15%
Mode of acquisition / sale (e.g. open market / off-market /public issue / rights issue / preferential allotment / inter-se transfer etc).		Off market inter-se transfer		
Date of acquisition/sale of shares/VR or date of receipt of intimation of allotment of shares, whichever is applicable		17 th September, 2021		
Equity share capital/total voting capital of the TC before the said acquisition/sale		Rs. 7,46,43,510/-		
Equity share capital/ total voting capital of the TC after the said acquisition/sale		Rs. 7,46,43,510/-		
Total diluted share/voting capital of the TC after the said acquisition		Rs. 7,46,43,510/- **There are no outstanding convertible securities/warrants.		

(*)Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**)Diluted share/ voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Pharmaceutical Business Group (India) Limited



Kersasp Kalianwala

Director

Place: Mumbai

Date: 18th September, 2021





YUHAN

74, Noryangjin-ro, Dongjak-gu, Seoul, Korea
Phone 82-2-828-0181 / Fax 82-2-828-0300

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad,
Gujarat- 396195

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2019 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,

Yours Faithfully,
For YUHAN CORPORATION

Authorized Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea
Date: April, 2nd 2019



YUHAN

74, Noryangjin-ro, Dongjak-gu, Seoul, Korea
Phone 82-2-828-0181 / Fax 82-2-828-0300

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2018 under Regulation 30(1) & 30(2) of
SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,
Yours Faithfully,
For YUHAN CORPORATION

Authorized Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea
Date: April, 2nd 2019

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


ANNEXURE – 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder			
a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC.			
or			
b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	YUHAN CORPORATION Promoter Group & PAC: Part B		
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2019, holding of:			
a) Shares	3850000	26.50	NA
Shares (Total Promoter Group & PAC)	7045745	48.50	NA
b) Voting Rights (otherwise than by shares)	NA	NA	NA
c) Warrants,	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Yours Faithfully,
For YUHAN CORPORATION


Authorized Signatory

Name of Signatory: NamJin Park

Designation: Executive Director

Date: April, 2nd 2019

Part - B

Member of the Promoter Group & Persons Acting In Concert (PAC)

YUHAN CORPORATION

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	YUHAN CORPORATION	3850000	26.50	AAACY6532E	Promoter Group
2.	PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD	3582000	24.65	AAACP3123E	Promoter Group
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter Group
4.	JAYSHREE DINESH PATEL	70645	0.49	AGBFP4254G	Promoter Group
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter Group
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter Group
7.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter Group
8.	ANAY RUPEN CHOKSI	3047	0.02	AHSPC2187K	Promoter Group
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter Group
TOTAL		10895745	74.99		

Yours Faithfully,

For YUHAN CORPORATION



Director/Authorised Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea

Date: April, 2nd 2019



YUHAN

74, Noryangjin-ro, Dongjak-gu, Seoul, Korea
Phone 82-2-828-0181 / Fax 82-2-828-0300

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2020 under Regulation 30(1) & 30(2) of
SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,
Yours Faithfully,
For YUHAN CORPORATION

A handwritten signature in black ink, appearing to read 'Namjin Park'.

Authorized Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea
Date: Jun, 1st 2020



YUHAN

74, Noryangjin-ro, Dongjak-gu, Seoul, Korea
Phone 82-2-828-0181 / Fax 82-2-828-0300

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad,
Gujarat- 396195

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2019 under Regulation 30(1) & 30(2) of
SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,

Yours Faithfully,
For YUHAN CORPORATION

Authorized Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea
Date: April, 2nd 2019

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


ANNEXURE – 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder	YUHAN CORPORATION Promoter Group & PAC: Part B		
a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.			
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2020, holding of:			
a) Shares	3850000	26.50	NA
Shares (Total Promoter Group & PAC)	7045745	48.50	NA
b) Voting Rights (otherwise than by shares)	NA	NA	NA
c) Warrants,	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Yours Faithfully,
For YUHAN CORPORATION


Authorized Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Date: Jun, 1st 2020

Part - B

Member of the Promoter Group & Persons Acting In Concert (PAC)

YUHAN CORPORATION

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voiting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	YUHAN CORPORATION	3850000	26.50	AAACy6532E	Promoter Group
2.	PHARMACEUTICAL BUSINESS GROUP (INDIA) LTD	3582000	24.65	AAACP3123E	Promoter Group
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter Group
4.	JAYSHREE DINESH PATEL	70645	0.49	AGBPP4254G	Promoter Group
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter Group
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter Group
7.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter Group
8.	ANAY RUPEN CHOKSI	3047	0.02	AHSPC2187K	Promoter Group
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter Group
TOTAL		10895745	74.99		

Yours faithfully,

For YUHAN CORPORATION



Director/Authorised Signatory

Name of Signatory: Namjin Park

Designation: Executive Director

Place: Seoul, Korea

Date: Jun, 1st 2020

(On Letter head of Yuhan Corporation)

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad,
Gujarat- 396195

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2021 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,

Yours faithfully,
For YUHAN CORPORATION



Authorized Signatory

Name of Signatory: Han Kon Kim

Designation: General Manager

Place: Seoul, Korea
Date: Apr, 1st 2021

(On Letter head of Yuhan Corporation)

BSE Limited

PhirozeJeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,

**Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI
(Substantial Acquisition of Shares & Takeover) Regulations, 2011**

Enclosed please find disclosure as on March, 31st 2021 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,
Yours Faithfully,
For YUHANCORPORATION



Authorized Signatory

Name of Signatory: Han Kon Kim

Designation: General Manager

Place: Seoul, Korea
Date: Apr, 1st 2021

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

ANNEXURE – 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	YUHAN CORPORATION Promoter Group & PAC: Part B		
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2021, holding of:			
a) Shares	3850000	26.50	NA
Shares (Total Promoter Group & PAC)	7045745	48.50	NA
b) Voting Rights (otherwise than by shares)	NA	NA	NA
c) Warrants,	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Yours Faithfully,

For YUHAN CORPORATION


Authorized Signatory

Name of Signatory: Han Kon Kim

Designation: General Manager

Date: Apr, 1st 2021

Part - B

Member of the Promoter Group & Persons Acting In Concert (PAC)

YUHAN CORPORATION

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	YUHAN CORPORATION	3850000	26.50	AAACY632E	Promoter Group
2.	PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD	3582000	24.65	AAACP3123E	Promoter Group
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter Group
4.	JAYSHREE DINESH PATEL	70645	0.49	AGBPP4254G	Promoter Group
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter Group
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter Group
7.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter Group
8.	ANAY RUPEN CHOKSI	3047	0.02	AHSPC2187K	Promoter Group
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter Group
TOTAL		10895745	74.99		

Yours faithfully,

For YUHAN CORPORATION



Director/Authorised Signatory

Name of Signatory: Han Kon Kim

Designation: General Manager

Place: Seoul, Korea

Date: Apr, 1st 2021

Pharmaceutical
Business Group
(India) Limited

Regd. Office : Parijat House, 1076, Dr. E. Moses Road, Worli, Bombay - 400 018.
Tel. : 492 27 26, 492 27 28, 492 26 69, 492 24 55
Telex: 011-73734 PACS IN/73848 OCAN IN Fax: 495 03 63/495 03 14

CIN: U24239MH1991IPLC059995

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad,
Gujarat - 396195

Dear Sir/Madam,

Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Enclosed please find disclosure as on March 31, 2019 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.


Jayshree D. Patel
Director



Place: Mumbai
Date: 03.04.2019

Encl: as above

**Pharmaceutical
Business Group
(India) Limited**

Regd. Office : Parijat House, 1076, Dr. E. Moses Road, Worli, Bombay - 400 018.

Tel. : 492 27 26, 492 27 28, 492 26 69, 492 24 55

Telex : 011-73734 PACS IN/73848 OCAN IN Fax : 495 03 63/495 03 14

CIN: U24239MH1991IPLC059995

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,


Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Enclosed please find disclosure as on March 31, 2019 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,
Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.


Jayshree D. Patel
Director



Place: Mumbai
Date: 03.04.2019

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

ANNEXURE – 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	Pharmaceutical Business Group (I) Ltd. Promoter Group & PAC : Part B		
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2019, holding of:			
a) Shares	3582000	24.65	NA
Shares (Promoter Group & PAC)	7313745	50.34	NA
b) Voting Rights (otherwise than by shares)	NA	NA	NA
c) Warrants,	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.

Jayshree D. Patel
Director

Place: Mumbai

Date: 03.04.2019



Part - B

Member of the Promoter Group & Persons Acting In Concert (PAC)

Pharmaceutical Business Group (India) Ltd.

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter
2.	PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD	3582000	24.65	AAACP3123E	Promoter
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter
4.	JAYSHREE DINESH PATEL	70645	0.49	AGBPP4254G	Promoter
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter
7.	YUHAN CORPORATION	3850000	26.50	AAACY6532E	Promoter
8.	ANAY RUPEN CHOKSI	3047	0.02	AHSPC2187K	Promoter
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter
TOTAL		10895745	74.99		

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.

Jayshree D. Patel
Director

Place: Mumbai
Date: 03.04.2019



Pharmaceutical
Business Group
(India) Limited

Regd. Office: Parijat House, 1076, Dr. E. Moses Road, Worli, Bombay - 400 018.
Tel.: 492 27 26, 492 27 28, 492 26 69, 492 24 55
Telex: 011-73734 PACS IN/73848 OCAN IN Fax: 495 03 63/495 03 14.

CIN: U24239MH19911PLC059995

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad
Gujarat - 396195

Dear Sir/Madam,

Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Enclosed please find disclosure as on March 31, 2020 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You.

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.


Jayshree D. Patel
Director

Place: Mumbai
Date: 12-05-2020

Encl: as above

Pharmaceutical
Business Group
(India) Limited

Regd. Office : Parijat House, 1076, Dr. E. Moses Road, Worli, Bombay - 400 018
Tel. : 492 27 26, 492 27 28, 492 26 69, 492 24 55
Telex : 011-73734 PACS IN/73848 OCAN IN Fax : 495 03 63/495 03 14

CIN: U24239MH1991IPLC059995

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,


Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Enclosed please find disclosure as on March 31, 2020 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011

Kindly take this on your record.

Thanking You,
Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.



Jayshree D. Patel
Director

Place: Mumbai
Date: 12-05-2020

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

ANNEXURE – 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Therms Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	Pharmaceutical Business Group (I) Ltd. Promoter Group & PAC - Part B		
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2020, holding of:			
a) Shares	3582000	24.65	NA
Shares (Promoter Group & PAC)	7313745	50.34	NA
b) Voting Rights (otherwise than by shares)	NA	NA	NA
c) Warrants	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.

Jayshree D. Patel
Director

Place: Mumbai

Date: 12-05-2020

Part - B

Member of the Promoter Group & Persons Acting in Concert (PAC)

Pharmaceutical Business Group (India) Ltd.

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter
2.	PHARMACEUTICAL BUSINESS GROUP (INDIA) LTD.	3582000	24.65	AAACP3123E	Promoter
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter
4.	JAYSHREE DINESH PATEL	70645	0.49	AG8PP4254C	Promoter
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter
7.	YUHAN CORPORATION	3850000	26.50	AAACY6532E	Promoter
8.	ANAY RUPEN CHOKSI	3047	0.02	AH5PC2167Y	Promoter
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter
	TOTAL	10895745	74.99		

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd

Jayshree D. Patel
Director

Place: Mumbai
Date: 12-05-2020

Pharmaceutical
Business Group
(India) Limited

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

The Board of Directors
Gujarat Themis Biosyn Ltd
69/C, GIDC Industrial Estate,
Vapi, Valsad,
Gujarat - 396195

Dear Sir/Madam,

Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.


Enclosed please find disclosure as on March 31, 2021 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,

Yours Faithfully,

For PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD



Dr. Sachin D. Patel

Director

DIN: 00033353

Place: Mumbai

Date: 05/04/2021

Encl: as above

Pharmaceutical
Business Group
(India) Limited

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104"
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070. EMAIL: raveendran@themismedicare.com

CIN:U24239MH1991IPLC059995

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai- 400 001.

Dear Sir/Madam,

Sub: Disclosure of shareholding under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Enclosed please find disclosure as on March 31, 2021 under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Kindly take this on your record.

Thanking You,
Yours Faithfully,

For PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD



Dr. Sachin D. Patel
Director
DIN: 00033353

Place: Mumbai
Date: 05/04/2021

Encl: as above

ANNEXURE - 1

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited		
3. Particulars of the shareholder			
a. Name of person whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the share or voting rights of the TC.			
or			
b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	Pharmaceutical Business Group (I) Ltd Promoter Group & PAC : Part B		
4. Particulars of the holding of persons mentioned at (3) above	Number	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
5. As on March 31 of 2021, holding of:			
a) Shares			
Shares (Promoter Group & PAC)	3582000	24.65	NA
b) Voting Rights (otherwise than by shares)	7313745	50.34	NA
c) Warrants,	NA	NA	NA
d) Convertible Securities	NA	NA	NA
e) Any other instrument that would entitle the holder to receive shares in the TC.	NA	NA	NA

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Yours Faithfully

For Pharmaceutical Business Group (India) Ltd.

Dr. Sachin D. Patel

Director

DIN: 00033353

Place: Mumbai

Date: 05/04/2021

Part - B

Member of the Promoter Group & Persons Acting In Concert (PAC)


Pharmaceutical Business Group (India) Ltd.

Name of the Target Company: Gujarat Themis Biosyn Ltd.

Sr. No.	Name Of Promoter/ PAC	Number Of Shares	% W. R. T. Total Share /Voting Capital Wherever Applicable	PAN	Promoter/ Promoter group
1.	DINESH SHANTILAL PATEL	4701	0.03	AACPP9037A	Promoter
2.	PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD	3582000	24.65	AAACP3123E	Promoter
3.	THEMIS MEDICARE LIMITED	3369605	23.19	AABCT1183B	Promoter
4.	JAYSHREE DINESH PATEL	70645	0.49	AGBPP4254G	Promoter
5.	SACHIN DINESH PATEL	7100	0.05	AACPP9039Q	Promoter
6.	REENA SACHIN PATEL	5600	0.04	AAZPP8647F	Promoter
7.	YUHAN CORPORATION	3850000	26.50	AAACY6532E	Promoter
8.	ANAY RUPEN CHOKSI	3047	0.02	AHSPC2187K	Promoter
9.	NYSHA RUPEN CHOKSI	3047	0.02	AKVPC0268R	Promoter
TOTAL		10895745	74.99		

Yours Faithfully,

For Pharmaceutical Business Group (India) Ltd.


Dr. Sachin D. Patel
Director
DIN: 00033353

Place: Mumbai
Date: 05/04/2021